161 studies found for:    b47
Show Display Options
Rank Status Study
1 Active, not recruiting Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Conditions: Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Doxorubicin Hydrochloride;   Drug: Docetaxel;   Drug: Cyclophosphamide;   Biological: Trastuzumab;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
2 Active, not recruiting A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: L-DOS47
3 Recruiting X-chromosome Inactivation, Epigenetics and the Transcriptome
Conditions: Turner Syndrome;   Klinefelter Syndrome;   Triple X Syndrome;   47 XYY Syndrome;   Aortic Aneurysm
Intervention:
4 Recruiting Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)
Condition: Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4)
Intervention: Drug: ND-L02-s0201 Injection
5 Active, not recruiting Cognitive Changes Associated With Breast Cancer Treatment
Conditions: Breast Cancer;   Cognitive Side Effects of Cancer Treatments;   Stage I, II and III A Breast Cancer
Intervention: Behavioral: Questionnaires, MRI, Comet assay and Cell senescence
6 Unknown  Entecavir for Chronic Hepatitis B in Hepatocellular Carcinoma Patients Underwent Radiofrequency Ablation Therapy
Conditions: Chronic Hepatitis B;   Hepatocellular Carcinoma
Intervention: Drug: Entecavir
7 Completed
Has Results
BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Interferon beta-1b (Betaseron, BAY86-5046)
8 Recruiting Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28
Conditions: Meningoccocal Disease,;   Meningococcal Meningitis
Interventions: Biological: rMenB + OMV vaccine (1 dose at study month zero);   Biological: rMenB + OMV vaccine (2 doses 1 month apart)
9 Active, not recruiting Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine
Condition: Malaria
Interventions: Biological: Pfs25-EPA/Alhydrogel;   Biological: Euvax B;   Biological: Menactra
10 Completed Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Condition: Meningococcal Disease
Interventions: Biological: Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1);   Biological: Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2);   Biological: Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3);   Biological: Routine vaccination;   Biological: Meningococcal group C
11 Completed
Has Results
Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers
Condition: Meningococcal Disease
Interventions: Biological: 1a - rMenB+OMV NZ and routine vaccines;   Biological: 1b - rMenB+OMV NZ and routine vaccines;   Biological: 2a - Routine and rMenB+OMV NZ vaccines;   Biological: 2b - rMenB+OMV NZ and routine vaccines;   Biological: 3a - rMenB+OMV NZ and routine vaccines;   Biological: 3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations;   Biological: 4a- rMenB+OMV NZ and routine vaccines;   Biological: 4b - rMenB+OMV NZ and routine vaccines
12 Unknown  The Beneficial Effect of Vitamin D Supplement to Peg Interferon Alpha 2a or to Telbivudine Monotherapy in Patients With Chronic Hepatitis B Virus (HBV) Infection
Condition: Hepatitis B Virus
Interventions: Drug: Peginterferon + Vitamin D;   Drug: Peginterferon;   Drug: Sebivo;   Drug: entecavir+ vitamin d
13 Recruiting B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study.
Condition: Chronic Fatigue Syndrome/ Myalgic Encephalitis (CFS/ME)
Interventions: Drug: Rituximab;   Drug: Placebo
14 Recruiting B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome
Conditions: Chronic Fatigue Syndrome;   Myalgic Encephalomyelitis
Intervention: Drug: Rituximab
15 Completed Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Interventions: Biological: rMenB+OMV NZ with routine vaccinations;   Biological: rMenB+OMV NZ;   Biological: two doses of rMenB+OMV NZ
16 Completed 4 Versus 6 Courses of Adjuvant Chemotherapy in LACC Patients Previously Treated With NACT Plus Radical Surgery
Condition: Uterine Cervical Neoplasms
Interventions: Procedure: Group A adjuvant chemotherapy;   Procedure: Group B adjuvant chemotherapy;   Drug: Cisplatin;   Drug: Paclitaxel
17 Completed Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
Conditions: Adult Acute Basophilic Leukemia;   Adult Acute Eosinophilic Leukemia;   Adult Acute Erythroid Leukemia (M6);   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Childhood Acute Basophilic Leukemia;   Childhood Acute Eosinophilic Leukemia;   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myelomonocytic Leukemia (M4);   Childhood Myelodysplastic Syndromes;   de Novo Myelodysplastic Syndromes;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: valspodar;   Biological: filgrastim;   Drug: busulfan;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Biological: aldesleukin;   Other: clinical observation;   Other: pharmacological study
18 Completed The Pharmacokinetics of Extended Duration High-dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study
Condition: Gonorrhoea
Intervention: Drug: Cefixime
19 Active, not recruiting A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX);   Biological: Placebo + Methotrexate  (MTX)
20 Completed
Has Results
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Conditions: Meningitis;   Meningococcal Infection
Interventions: Biological: MenACWY-CRM197;   Biological: DTaP (Diptheria, Tetanus, Pertussis) Vaccine;   Biological: Hib (Haemophilus influenza b) Vaccine;   Biological: IPV (Inactivated Polio Vaccine) Vaccine;   Biological: Pneumococcal conjugate Vaccine;   Biological: MMR (Measles, Mumps, and Rubella) Vaccine;   Biological: Varicella Vaccine;   Biological: Hepatitis A Virus

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years